BR112021022457A2 - Inibidores de fgfr e métodos de uso dos mesmos - Google Patents

Inibidores de fgfr e métodos de uso dos mesmos

Info

Publication number
BR112021022457A2
BR112021022457A2 BR112021022457A BR112021022457A BR112021022457A2 BR 112021022457 A2 BR112021022457 A2 BR 112021022457A2 BR 112021022457 A BR112021022457 A BR 112021022457A BR 112021022457 A BR112021022457 A BR 112021022457A BR 112021022457 A2 BR112021022457 A2 BR 112021022457A2
Authority
BR
Brazil
Prior art keywords
methods
fgfr
fgfr inhibitors
compounds
compositions
Prior art date
Application number
BR112021022457A
Other languages
English (en)
Inventor
Alessandro Boezio
M Taylor Alexander
Bakary-Barry Touré
M Hudson Brandi
T Moustakas Demetri
A Sharon Dina
Fabrizio Giordanetto
Heike Schoenherr
M Mader Mary
Pelin Ayaz
Ravi Kurukulasuriya
H Mclean Thomas
Original Assignee
De Shaw Res Llc
Relay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Shaw Res Llc, Relay Therapeutics Inc filed Critical De Shaw Res Llc
Publication of BR112021022457A2 publication Critical patent/BR112021022457A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

inibidores de fgfr e métodos de uso dos mesmos. a presente invenção refere-se a novos compostos e composições farmacêuticas dos mesmos, e métodos para inibir a atividade de enzimas de fgfr com os compostos e composições da invenção. a presente invenção também se refere a, mas não está limitada a, métodos para o tratamento de distúrbios associados com sinalização de fgfr com o compostos e composições da invenção.
BR112021022457A 2019-05-13 2020-05-12 Inibidores de fgfr e métodos de uso dos mesmos BR112021022457A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962846991P 2019-05-13 2019-05-13
US202062993957P 2020-03-24 2020-03-24
US202063011469P 2020-04-17 2020-04-17
PCT/US2020/032474 WO2020231990A1 (en) 2019-05-13 2020-05-12 Fgfr inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112021022457A2 true BR112021022457A2 (pt) 2022-03-22

Family

ID=73289291

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022457A BR112021022457A2 (pt) 2019-05-13 2020-05-12 Inibidores de fgfr e métodos de uso dos mesmos

Country Status (15)

Country Link
US (2) US20230104574A1 (pt)
EP (2) EP3968999B1 (pt)
JP (1) JP7527309B2 (pt)
KR (1) KR20220007889A (pt)
CN (1) CN114126620A (pt)
AU (1) AU2020274083A1 (pt)
BR (1) BR112021022457A2 (pt)
CA (1) CA3137458A1 (pt)
CL (1) CL2021002882A1 (pt)
ES (1) ES2974985T3 (pt)
IL (1) IL287940A (pt)
MX (1) MX2021013146A (pt)
PE (1) PE20220573A1 (pt)
SG (1) SG11202111327XA (pt)
WO (1) WO2020231990A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020274083A1 (en) 2019-05-13 2021-11-18 D.E. Shaw Research, Llc FGFR inhibitors and methods of use thereof
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
CN115160319B (zh) * 2021-04-01 2023-12-26 西安新通药物研究股份有限公司 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
TW202304889A (zh) * 2021-04-03 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 作為fgfr抑制劑的雜環化合物及其應用
CN117677621A (zh) * 2021-08-04 2024-03-08 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
WO2023046117A1 (en) * 2021-09-23 2023-03-30 3H Pharmaceuticals Co., Ltd. Fgfr inhibitors and methods of use thereof
CN118369322A (zh) * 2021-12-06 2024-07-19 英矽智能科技(上海)有限公司 取代的单环或双环杂环化合物，其制法与医药上的用途
AU2023219447A1 (en) * 2022-02-08 2024-09-26 Etern Biopharma (Shanghai) Co., Ltd. Bicyclic heteroaryl compounds and uses thereof
CN116903628A (zh) * 2022-04-20 2023-10-20 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法
TW202400175A (zh) * 2022-05-10 2024-01-01 美商傳達治療有限公司 PI3Kα抑制劑及其使用方法
WO2024002157A1 (en) * 2022-06-29 2024-01-04 Insilico Medicine Ip Limited Inhibitors of fgfr2 and fgfr3 and uses thereof
WO2024002223A1 (zh) * 2022-06-29 2024-01-04 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
CN115594682B (zh) * 2022-10-26 2024-03-15 苏州浦合医药科技有限公司 Fgfr2抑制剂
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用
WO2024175121A1 (zh) * 2023-02-24 2024-08-29 希格生科（深圳）有限公司 α，β-不饱和酰胺类化合物及其应用
WO2024193542A1 (en) * 2023-03-20 2024-09-26 Insilico Medicine Ip Limited Inhibitors of fgfr2 and fgfr3 and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
EP0938486B1 (en) * 1996-08-23 2008-01-16 Novartis AG Substituted pyrrolopyrimidines and processes for their preparation
KR20000076426A (ko) 1997-03-19 2000-12-26 스타르크, 카르크 피롤로[2,3-ｄ]피리미딘 및 티로신 키나제 저해제로서의 그의 용도
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
US7323469B2 (en) * 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
CA2536887C (en) * 2003-08-26 2012-03-06 Teijin Pharma Limited Pyrrolopyrimidinone derivatives
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
WO2006004703A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
US7776867B2 (en) * 2004-06-29 2010-08-17 Amgen Inc. Furanopyrimidines
DE102005061170A1 (de) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
EP2424368B1 (en) * 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102286048A (zh) * 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
PT3269370T (pt) * 2016-02-23 2020-03-05 Taiho Pharmaceutical Co Ltd Novo composto de pirimidina condensada ou sal do mesmo
WO2018049233A1 (en) * 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
CN117327075A (zh) 2017-01-23 2024-01-02 锐新医药公司 作为变构shp2抑制剂的二环化合物
KR20220113545A (ko) 2017-03-23 2022-08-12 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
AU2020274083A1 (en) 2019-05-13 2021-11-18 D.E. Shaw Research, Llc FGFR inhibitors and methods of use thereof
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法

Also Published As

Publication number Publication date
IL287940A (en) 2022-01-01
US20230104574A1 (en) 2023-04-06
EP4306529A2 (en) 2024-01-17
US11780845B2 (en) 2023-10-10
EP3968999B1 (en) 2023-12-27
EP4306529A3 (en) 2024-04-10
JP2022533570A (ja) 2022-07-25
US20230192709A1 (en) 2023-06-22
PE20220573A1 (es) 2022-04-20
CA3137458A1 (en) 2020-11-19
TW202108141A (zh) 2021-03-01
KR20220007889A (ko) 2022-01-19
SG11202111327XA (en) 2021-11-29
CN114126620A (zh) 2022-03-01
EP3968999A4 (en) 2022-08-03
ES2974985T3 (es) 2024-07-02
EP3968999A1 (en) 2022-03-23
WO2020231990A1 (en) 2020-11-19
MX2021013146A (es) 2022-01-24
JP7527309B2 (ja) 2024-08-02
CL2021002882A1 (es) 2022-10-07
AU2020274083A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
BR112022004451A2 (pt) Antagonistas de hpk1 e usos dos mesmos
BR112022021854A2 (pt) Inibidores de fosfatidilinositol 3-quinase alfa e mé-todos de uso dos mesmos
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
BR112015032595A2 (pt) inibidores de ido
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
AR126447A1 (es) INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
BR112021023635A2 (pt) Novos compostos para inibição de janus quinase 1
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
AR129281A1 (es) INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS
BR112019023109A2 (pt) Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo